肿瘤细胞治疗研究
英文原题：CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond.
CD70 是抗癌治疗中新兴的靶点。
CD70是新兴的抗癌治疗靶点。由于其在正常生理组织中的表达有限，却易在多种恶性肿瘤中异常表达，因此是理想的抗原靶点，有望限制脱靶毒性。CD70还深度参与免疫稳态，干扰该通路有助于克服肿瘤相关免疫细胞耗竭。近期采用靶向CD70细胞疗法（如CAR-T 细胞）的I/II期临床试验，在治疗复发或难治性肾细胞癌方面显示出良好的有效性和安全性。非细胞疗法也在研发中，包括抗体药物偶联物、单克隆抗体、放射性核素及细胞因子，早期数据同样令人鼓舞。进一步提升和优化CD70靶向疗法的研究也已开展。
CD70 is an emerging target for anticancer therapies. It is an ideal antigen target given its limited expression in normal physiologic tissues and propensity to be aberrantly expressed in a variety of malignancies, thus limiting off-target toxicities. It is also heavily involved in immune homeostasis, and disruption of this pathway can help overcome tumor-related immune cell exhaustion. Recent phase I/II trials using cellular therapies targeting CD70, such as chimeric antigen receptor-T cells, have shown promising effectiveness and safety in treating relapsed or refractory renal cell carcinoma. Noncellular therapies targeting CD70, such as antibody-drug conjugates, monoclonal antibodies, radionuclides, and cytokines, are currently under investigation, with early data showing encouraging results as well. Efforts are already underway to further improve and optimize CD70-based therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
